Mirae Asset Global Investments Co. Ltd. Purchases 1,331 Shares of Inhibrx, Inc. (NASDAQ:INBX)

Mirae Asset Global Investments Co. Ltd. increased its position in Inhibrx, Inc. (NASDAQ:INBX) by 6.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,494 shares of the company’s stock after buying an additional 1,331 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Inhibrx were worth $779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Swiss National Bank lifted its position in Inhibrx by 2.1% in the 3rd quarter. Swiss National Bank now owns 57,600 shares of the company’s stock worth $1,057,000 after buying an additional 1,200 shares during the last quarter. Citigroup Inc. lifted its position in Inhibrx by 3.4% in the third quarter. Citigroup Inc. now owns 49,244 shares of the company’s stock valued at $904,000 after purchasing an additional 1,611 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Inhibrx by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,705 shares of the company’s stock valued at $255,000 after purchasing an additional 1,700 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Inhibrx by 389.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,471 shares of the company’s stock valued at $208,000 after purchasing an additional 4,354 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in Inhibrx in the fourth quarter valued at approximately $209,000. Institutional investors own 82.46% of the company’s stock.

Analysts Set New Price Targets

INBX has been the subject of a number of recent analyst reports. Lifesci Capital downgraded Inhibrx from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 23rd. JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Tuesday, January 23rd.

Inhibrx Trading Up 0.7 %

NASDAQ INBX opened at $34.38 on Thursday. Inhibrx, Inc. has a 12 month low of $14.31 and a 12 month high of $39.79. The stock has a market cap of $1.63 billion, a P/E ratio of -6.83 and a beta of 2.91. The stock’s fifty day moving average price is $35.66 and its 200-day moving average price is $30.11. The company has a current ratio of 5.24, a quick ratio of 5.25 and a debt-to-equity ratio of 4.78.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.66). The business had revenue of $1.63 million for the quarter, compared to the consensus estimate of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. As a group, equities analysts forecast that Inhibrx, Inc. will post -4.34 EPS for the current fiscal year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.